Ra Pharma's $2.1B Sale Hits Merger Review Snag At FTC
Biotech developer Ra Pharmaceuticals Inc. has run up against potential delays in getting its $2.1 billion deal to be gobbled up by Belgium's UCB approved, saying Tuesday that it pulled the...To view the full article, register now.
Already a subscriber? Click here to view full article